Retatrutide Canada: Research Reference and Batch Documentation
Retatrutide Canada is a research-reference and batch-documentation page covering LY3437943 and PeptideProCanada’s 10mg, 20mg, and 30mg laboratory material listings. It provides scientific identifiers, published source links, and access to available analytical records.
Retatrutide is also identified in published research as LY3437943. It is an investigational single-molecule triple hormone receptor agonist studied for activity at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.
Retatrutide, also identified as LY3437943, remains an investigational research compound. PPC represents the linked 10mg, 20mg, and 30mg materials solely for non-clinical laboratory research, with available batch-specific analytical documentation published on the related listing pages.
Retatrutide Canada Laboratory Material Listings
PeptideProCanada maintains separate pages for its 10mg, 20mg, and 30mg listings so that the identifier, vial image, SKU, batch information, and posted analytical documentation remain specific to the material shown.
Visible Batch Documentation
A generic statement that a material is “tested” is not the same as publishing report-level evidence. Where documentation is posted, readers can review the laboratory name, report identifier, tested material, analytical result, and related batch information for the applicable listing.
Format-specific reports
The 10mg, 20mg, and 30mg listings maintain their own product images and supporting documentation instead of relying on one generic Retatrutide claim.
Batch traceability
Vial identifiers can be compared with the documentation shown on the corresponding product page, helping laboratories confirm that they are reviewing the relevant record.
Independent analysis
Posted reports identify the independent laboratory and the analytical work represented. The report itself—not a marketing badge—should be treated as the source record.
Current-page access
Documentation is placed on the applicable product page so researchers do not need to request a generic or unidentified certificate before reviewing a listing.
What Is Retatrutide?
Retatrutide is the research name for LY3437943, an investigational peptide designed as a single molecule with agonist activity at three receptor systems: GIP, GLP-1, and glucagon. Scientific literature commonly describes this architecture as a triple hormone receptor agonist or triple agonist.
Retatrutide has been evaluated in registered clinical studies, but those programs concern the developer’s investigational drug and controlled trial material. Their findings cannot be attributed to independently supplied laboratory materials and do not establish the identity, purity, sterility, safety, efficacy, or suitability of any PPC-listed material. PPC does not represent its materials as the investigational drug used in those trials.
| Research reference | Description |
|---|---|
| Common name | Retatrutide |
| Research identifier | LY3437943 |
| Research classification | Single-molecule GIP, GLP-1, and glucagon receptor agonist |
| Development status | Investigational; clinical research remains active |
| PPC laboratory formats | 10mg, 20mg, and 30mg lyophilized research reagent vials |
Retatrutide and the Triple-Agonist Research Model
The compound’s research interest comes from the study of three receptor pathways in one molecular design. This differs from single- and dual-receptor incretin research models. The table below describes the classification only; it is not a treatment comparison or a statement that any PPC material is suitable for administration.
| Research compound | Receptor model | General research distinction |
|---|---|---|
| Semaglutide | GLP-1 receptor agonism | Single-receptor incretin model |
| Tirzepatide | GIP and GLP-1 receptor agonism | Dual-receptor incretin model |
| Retatrutide | GIP, GLP-1, and glucagon receptor agonism | Triple-receptor research model |
Retatrutide is sometimes called “GLP-3” in informal online discussions. That term is not a recognized scientific classification. “Triple agonist” or “GIP/GLP-1/glucagon receptor agonist” is more accurate because the compound does not act on a receptor called GLP-3.
Published Research and Current Development Status
Retatrutide has been studied across several controlled clinical research programs. These sources are included to document the compound’s scientific context, not to provide personal-use guidance or imply that laboratory research materials are approved medications.
- A 2023 Phase 2 publication concerning the developer’s investigational retatrutide material is indexed by PubMed.
- A separate 2023 Phase 2 publication concerning the developer’s investigational material is also indexed by PubMed.
- The TRIUMPH clinical program includes registered Phase 3 research. Current study information is available from ClinicalTrials.gov.
- The developer’s current overview provides additional background on the compound and its ongoing clinical-development program. See Lilly’s retatrutide information page.
Intended Use and Listing Restrictions
Non-clinical purpose
The linked materials are represented solely for non-clinical laboratory research, analytical reference work, and controlled assay development.
No administration
The materials are not represented or supplied for human or animal administration, consumption, treatment, diagnosis, or personal experimentation.
Record review
Listing identifiers, batch information, and available analytical records should be reviewed against the requirements of the applicable laboratory setting.
Purchaser responsibility
Purchasers must be 21 or older and are responsible for determining and complying with all institutional, local, provincial, and federal requirements that apply to their activities.
Retatrutide Canada FAQ
What is Retatrutide?
Retatrutide, also known as LY3437943, is an investigational single-molecule triple agonist studied for activity at the GIP, GLP-1, and glucagon receptors.
What Retatrutide Canada formats does PeptideProCanada list?
PeptideProCanada currently lists separate 10mg, 20mg, and 30mg lyophilized laboratory research reagent formats.
Where can I review Retatrutide batch COAs?
Available batch-specific analytical documentation is published on the corresponding 10mg, 20mg, or 30mg product page. The format cards above link directly to those pages.
Is “GLP-3” another scientific name for Retatrutide?
No. “GLP-3” is an informal online nickname, not a scientific receptor classification. Retatrutide is more accurately described as a GIP, GLP-1, and glucagon receptor triple agonist.
Is PeptideProCanada’s Retatrutide intended for human or animal use?
No. PPC represents and supplies the listed materials solely for non-clinical laboratory research, not for human or animal consumption, administration, diagnosis, treatment, or personal use.
Does published Retatrutide research validate PPC-listed material?
No. Published studies concern the developer’s controlled investigational material. They do not establish the identity, quality, performance, or suitability of independently supplied laboratory material.
Research-use-only notice: PPC represents and supplies all materials linked from this page solely for non-clinical laboratory research, analytical reference work, and controlled assay development. They are not represented or supplied for human or animal consumption, administration, clinical or therapeutic use, diagnosis, cosmetic use, or personal experimentation. Handle only under appropriate institutional procedures and applicable requirements.